Dyrk1b as a potential biomarker for sarcopenia in older adults

Abstract

Background: Sarcopenia is characterized by the progressive loss of muscle mass and function due to aging. Dual-specificity tyrosine-regulated kinase 1b (Dyrk1b) plays a key role in muscle differentiation by regulating transcription, cell cycle progression, and cell survival. However, the relationship between Dyrk1b levels and sarcopenia is unclear. This study aimed to evaluate the association of serum Dyrk1b level with sarcopenia in the elderly of community-dwelling. Methods: A total of 939 community-dwelling elderly people (median age = 76.0 years) were recruited, including 524 men and 415 women. Serum Dyrk1b was measured by enzyme-linked immunosorbent assay. Appendicular skeletal muscle mass index (ASMI), grip strength, and gait speed were taken to assess sarcopenia. Results: We found that serum Dyrk1b levels in patients with sarcopenia [median (IQR) = 67.37 (55.13–82.56) pg/mL] were lower than those in elderly people without sarcopenia [70.40 (58.34–92.35) pg/mL, P < 0.001]. Receiver operating characteristic curve analysis indicated that the optimal cutoff value of serum Dyrk1b level for predicting sarcopenia was 44.73 pg/mL, with a sensitivity of 94.8% and a specificity of 14.7% (AUC = 0.577, 95% CI = 0.540–0.613, P < 0.001. Multivariate logistic regression analysis showed that high serum Dyrk1b levels (> 44.73 pg/mL) were related to decreased risk of sarcopenia (adjusted OR = 0.342, 95%CI = 0.194–0.603, P < 0.001). Moreover, serum Dyrk1b concentration was positively correlated with ASMI (r = 0.169, P < 0.001), grip strength (r = 0.157, P < 0.001) and gait speed (r = 0.164, P < 0.001). Conclusions: In summary, our results indicate that low serum Dyrk1b level is associated with an increased risk of sarcopenia in the elderly, suggesting that Dyrk1b may be valuable as a surrogate biomarker for screening and evaluation of sarcopenia.